Latest News

LSP reports first closing of dementia fund

© Gerd Altmann/pixabay.com


by tg

European life sciences investors LSP has closed a new fund to fight dementia at €50m.

The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will be managed by Professor Philip Scheltens, a world-renowned dementia scientist and thought leader.

A staggering 50 million patients suffer from dementia worldwide, which is predicted to triple to 150 million before the year 2050. Gobal costs for healthcare systems are currently estimated to amount to over $800bn or 1.1% of global GDP. Yet, investments in R&D to find novel treatments are lagging behind.

The LSP Dementia Fund’s focus will be on finding novel treatments for neurodegenerative diseases, such as Alzheimer's disease, that cause dementia, as well as generating a strong financial return for investors.

LSP announced it has yet raised €50m from strategic parties, financial institutions, and family offices. The investors believe the fund will ultimately reach at least €150m.

Valneva in talks with EU about 60 million vaccine doses

VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

COVID-19 test gives results within minutes

The method is published on MedRxiv, where the researchers headed by Professor Tim Dafforn from the University of Birmingham also...

German Health Ministry to invest €6.2bn in vaccines

With the request to the national budget committee, which will decide on it tomorrow, Germany more than doubles the amount of money to be invested...

EU orders additional COVID-19 vaccine doses

Under the new deal, the Commission has the option to request supply of an additional 100 million doses. This new agreement is in addition to the 300...

Abingworth raises US-$465m for new life sciences fund

UK-US venture capitalist Abingworth yesterday announced the final closing of its 13th life sciences venture fund, ABV 8, at US$465m exceeding...

Drug set to rescue COVID-19 patients at ICUs

Initial data from an US expanded access  (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

LSP reports first closing of dementia fund

The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...